荟萃分析:克罗恩病排除饮食用于克罗恩病诱导与维持治疗
该研究系统检索并荟萃分析了CDED对克罗恩病的临床有效性,纳入17项研究。CDED为基础干预在6-8周诱导临床缓解的合并率为0.69,维持缓解合并率为0.64,达到临床缓解的 odds 高于对照饮食,但临床反应 odds 无显著差异。
要点
- CDED为基础干预6-8周诱导临床缓解合并率为0.69(95%CI 0.65-0.74)。
- CDED较对照饮食提高临床缓解 odds(OR 2.58,95%CI 1.53-4.37)。
- 维持缓解合并率为0.64(95%CI 0.47-0.78),合并OR为2.73(95%CI 1.3-5.74)。
核心结论
- CDED为基础的饮食干预对诱导克罗恩病临床缓解可能有效。
- 仍需设计良好的随机试验进一步验证CDED作为全食物方案用于诱导和维持缓解。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Scopus(2025年2月10日)。
- 初筛508条题录,最终纳入17项研究,其中16项提供定量数据。
- 偏倚风险采用RoB-2.0、ROBINS-I和Joanna Briggs评估工具。
主要发现
- 6-8周CDED为基础干预诱导临床缓解合并率为0.69(95%CI 0.65-0.74,I2=0.0%)。
- 亚组分析:CDED+PEN、单用CDED、EEN诱导+CDED+PEN的缓解率分别为0.69(95%CI 0.63-0.75)、0.67(95%CI 0.57-0.76)、0.75(95%CI 0.61-0.85),I2均为0.0%。
- 6周临床反应合并率为0.83(95%CI 0.74-0.89,I2=0%)。
- 维持缓解合并率为0.64(95%CI 0.47-0.78,I2=73.5%)。
- 与对照饮食相比,达到临床缓解的OR为2.58(95%CI 1.53-4.37,I2=0%)。
关键数值与推荐
- 与EEN比较,6-12周达到临床缓解的OR为2.05(95%CI 1.13-3.74,I2=0%)。
- 与激素比较,达到临床缓解的OR为17.33(95%CI 1.75-171)。
- 与地中海饮食比较,达到临床缓解的OR为3.95(95%CI 1.14-13.71,I2=0.0%)。
- 临床反应的OR为2.36(95%CI 0.62-9.00,I2=42.4%),无显著差异。
- 维持缓解的合并OR为2.73(95%CI 1.3-5.74,I2=0%)。
临床怎么用
- CDED可作为克罗恩病诱导缓解的饮食治疗选择之一,尤其与PEN联合时。
- 对维持缓解也有一定支持证据,但异质性较高(I2=73.5%),需个体化评估。
- 生化、内镜、透壁和组织学结局数据有限,暂不能作为常规疗效判断依据。
局限性
- 仅有限数据涉及生化、内镜、透壁和组织学结局。
- 维持缓解合并率异质性较高(I2=73.5%)。
- 需设计良好的随机试验进一步验证CDED作为全食物方案的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a contemporary interest in dietary therapies for the treatment of inflammatory bowel disease. We performed a systematic review and meta-analysis to analyse the clinical effectiveness of the Crohn's disease exclusion diet (CDED) for Crohn's disease (CD). METHODS: We searched PubMed, Embase, and Scopus on 10th February 2025 to identify relevant studies using the terms 'Inflammatory bowel disease OR Crohn's disease' AND 'Crohn's disease exclusion diet'. We extracted information and estimated pooled rates for clinical response, clinical remission, and maintenance of remission with CDED alone, or with partial enteral nutrition (PEN), or exclusive enteral nutrition (EEN). We calculated the odds ratio for outcomes with CDED as compared to controls. Risk of Bias was estimated using RoB-2.0, ROBINS-I, and Joanna Briggs appraisal tools. RESULTS: Of the 508 titles, eventually 17 were included, and 16 studies provided quantitative data. The overall pooled rates for induction of clinical remission at 6-8 weeks with CDED-based interventions were 0.69 (95% CI: 0.65-0.74, I2 = 0.0%). On subgroup analysis, pooled clinical remission rates for CDED+PEN, CDED alone and EEN induction+CDED+PEN were 0.69 (95% CI: 0.63-0.75, I2 = 0.0%). 0.67 (95% CI: 0.57-0.76, I2 = 0.0%), 0.75 (95% CI: 0.61-0.85, I2 = 0.0%), respectively. The pooled rate of clinical response was 0.83 (0.74-0.89, I2 = 0%) at 6 weeks. The pooled rate of maintenance of remission was 0.64 (0.47-0.78, I2 = 73.5%). The overall odds of achieving clinical remission (2.58; 1.53-4.37, I2 = 0%) were higher compared to the control diet. On comparison with EEN, steroids and Mediterranean diet, the odds ratio to achieve clinical remission (6-12 weeks) was 2.05 (95% CI: 1.13-3.74, I2 = 0%), 17.33 (95% CI: 1.75-171), 3.95 (95% CI: 1.14-13.71, I2 = 0.0%), respectively. However, for clinical response (2.36; 95% CI: 0.62-9.00, I2 = 42.4%), the odds ratio was not significantly different. For maintenance of remission, the pooled odds ratio was 2.73 (95% CI: 1.3-5.74, I2 = 0%). Only limited data were available with respect to biochemical, endoscopic, transmural and histological outcomes. CONCLUSIONS: CDED-based dietary interventions appear to be efficacious for inducing remission in Crohn's disease. Well-designed randomised trials are required to further validate the use of CDED as a whole food approach in the induction and maintenance of remission in Crohn's Disease.
引用
- Batra G, Shukla A, Chatterjee A, et al. Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease. Aliment Pharmacol Ther. 2026. PMID: 42437372. doi:10.1111/apt.70857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。